

RECEIVED  
OPPT CBIC

2006 JAN -01 AM 8:29

201-16141B

# I U C L I D

## Data Set

Existing Chemical : ID: 7320-37-8  
CAS No. : 7320-37-8  
EINECS Name : tetradecyloxirane  
EC No. : 230-786-2  
Molecular Formula : C16H32O

Producer related part  
Company : Arkema Inc.  
Creation date : 20.12.2005

Substance related part  
Company : Arkema Inc.  
Creation date : 20.12.2005

Status :  
Memo :

Printing date : 23.12.2005  
Revision date :  
Date of last update : 23.12.2005

Number of pages : 43

Chapter (profile) : Chapter: 1, 2, 3, 4, 5, 6, 7, 8, 10  
Reliability (profile) : Reliability: without reliability, 1, 2, 3, 4  
Flags (profile) : Flags: without flag, confidential, non confidential, WGK (DE), TA-Luft (DE),  
Material Safety Dataset, Risk Assessment, Directive 67/548/EEC, SIDS

# 1. General Information

**Id** 7320-37-8  
**Date** 23.12.2005

## 1.0.1 APPLICANT AND COMPANY INFORMATION

**Type** : cooperating company  
**Name** : Arkema Inc.  
**Contact person** : Sandra Murphy  
**Date** : 20.12.2005  
**Street** : 2000 Market Street  
**Town** : PA 19103 Philadelphia  
**Country** : United States  
**Phone** : 215 419 5881  
**Telefax** : 215 419 5800  
**Telex** :  
**Cedex** :  
**Email** : sandi.murphy@arkemagroup.com  
**Homepage** :  
  
**Source** : Arkema Inc. Philadelphia, PA USA  
**Flag** : non confidential  
22.12.2005

## 1.0.2 LOCATION OF PRODUCTION SITE, IMPORTER OR FORMULATOR


## 1.0.3 IDENTITY OF RECIPIENTS

## 1.0.4 DETAILS ON CATEGORY/TEMPLATE

### 1.1.0 SUBSTANCE IDENTIFICATION

**IUPAC Name** :  
**Smiles Code** : O(C1CCCCCCCCCCCCC)C1  
**Molecular formula** : C16-H32-O  
**Molecular weight** : 240.42  
**Petrol class** :

**Source** : Arkema Inc. Philadelphia, PA USA  
**Attached document** : EHD.bmp



21.12.2005

# 1. General Information

**Id** 7320-37-8  
**Date** 23.12.2005

## 1.1.1 GENERAL SUBSTANCE INFORMATION

**Purity type** : typical for marketed substance  
**Substance type** : organic  
**Physical status** : liquid  
**Purity** : ca. 98 % w/w  
**Colour** : colorless  
**Odour** : ether-like odour

**Source** : Arkema Inc. Philadelphia, PA USA  
**Reliability** : Body weight data indicate a probable toxic effect at 10% and above in males and 20% and above in females.

22.12.2005

## 1.1.2 SPECTRA

**Type of spectra** : IR

**Attached document** : IR spectrum tetradecyloxirane.pdf

22.12.2005

(10)

## 1.2 SYNONYMS AND TRADENAMES

**1,2-epoxyhexadecane**

21.12.2005

**Vikolox (R) 16**

**Source** : Arkema Inc. Philadelphia, PA USA

22.12.2005

## 1.3 IMPURITIES

**Purity** : typical for marketed substance  
**CAS-No** : 629-73-2  
**EC-No** : 211-105-8  
**EINECS-Name** : hexadec-1-ene  
**Molecular formula** :  
**Value** : ca. 2 % w/w

**Source** : Arkema Inc. Philadelphia, PA USA

21.12.2005

## 1.4 ADDITIVES

## 1.5 TOTAL QUANTITY

## 1.6.1 LABELLING

**Symbols** : Xn, N, ,

## 1. General Information

Id 7320-37-8

Date 23.12.2005

**Nota** : , ,  
**R-Phrases** : (38) Irritating to skin  
(40) Possible risks of irreversible effects  
(51) Toxic to aquatic organisms  
(53) May cause long-term adverse effects in the aquatic environment  
**S-Phrases** :

21.12.2005

(3)

### 1.6.2 CLASSIFICATION

### 1.6.3 PACKAGING

### 1.7 USE PATTERN

**Type of use** : industrial  
**Category** : Chemical industry: used in synthesis  
**Remark** : Used primarily in the production of additives for functional fluids  
**Source** : Arkema Inc. Philadelphia, PA USA  
21.12.2005

#### 1.7.1 DETAILED USE PATTERN

**Industry category** : 3 Chemical industry: chemicals used in synthesis  
**Use category** : 33 Intermediates  
**Extra details on use category** : Substance processed elsewhere  
No extra details necessary  
**Emission scenario document** : available  
**Product type/subgroup** :  
**Tonnage for Application** :  
**Year** :  
**Fraction of tonnage for application** :  
**Fraction of chemical in formulation** :  
**Production** : yes:  
**Formulation** : :  
**Processing** : yes: III Multi-purpose equipment  
**Private use** :  
**Recovery** :  
**Source** : Arkema Inc. Philadelphia, PA USA  
21.12.2005

#### 1.7.2 METHODS OF MANUFACTURE

**Origin of substance** : Synthesis  
**Type** : Production  
**Source** : Arkema Inc. Philadelphia, PA USA  
21.12.2005

## 1.8 REGULATORY MEASURES

### 1.8.1 OCCUPATIONAL EXPOSURE LIMIT VALUES

### 1.8.2 ACCEPTABLE RESIDUES LEVELS

### 1.8.3 WATER POLLUTION

### 1.8.4 MAJOR ACCIDENT HAZARDS

### 1.8.5 AIR POLLUTION

### 1.8.6 LISTINGS E.G. CHEMICAL INVENTORIES

### 1.9.1 DEGRADATION/TRANSFORMATION PRODUCTS

### 1.9.2 COMPONENTS

### 1.10 SOURCE OF EXPOSURE

### 1.11 ADDITIONAL REMARKS

### 1.12 LAST LITERATURE SEARCH

**Type of search** : Internal and External  
**Chapters covered** : 3, 4, 5  
**Date of search** : 07.12.2005

21.12.2005

### 1.13 REVIEWS

## 2. Physico-Chemical Data

Id 7320-37-8  
Date 23.12.2005

### 2.1 MELTING POINT

Value : 21 °C  
Sublimation :  
Method :  
Year : 1999  
GLP :  
Test substance :

Source : Arkema Inc. Philadelphia, PA USA  
Reliability : (2) valid with restrictions  
22.12.2005

(21)

### 2.2 BOILING POINT

Value : = 270 - 275 °C at  
Decomposition :  
Method : other: micro, capillary visual  
Year :  
GLP :  
Test substance :

Remark : Literature values 104 - 106 C at 0.2 mm Hg  
Source : Arkema Inc. Philadelphia, PA USA  
Reliability : (2) valid with restrictions  
22.12.2005

(14)

### 2.3 DENSITY

Type : density  
Value : .846 at 20 °C

Source : ATOFINA Chemicals Inc. Philadelphia  
Reliability : (2) valid with restrictions  
22.12.2005

(21)

#### 2.3.1 GRANULOMETRY

### 2.4 VAPOUR PRESSURE

Value : ca. .00285 hPa at 25 °C  
Decomposition :  
Method : other (calculated)  
Year :  
GLP : no  
Test substance : no data

Result : Boiling Pt, Melting Pt, Vapor Pressure Estimations (MPBPWIN v1.41):

VP(mm Hg,25 deg C): 0.00214 (Modified Grain method)  
Source : Arkema Inc. Philadelphia, PA USA  
Reliability : (2) valid with restrictions  
22.12.2005

(7)

## 2.5 PARTITION COEFFICIENT

**Partition coefficient** : octanol-water  
**Log pow** : ca. 6.76 at 25 °C  
**pH value** :  
**Method** : other (calculated)  
**Year** :  
**GLP** : no  
**Test substance** : as prescribed by 1.1 - 1.4

**Method** : KOWWIN Program (v1.67)  
**Result** : WSKOW v1.41 Results -----  
 Log Kow (estimated) : 6.76  
 Log Kow (experimental): not available from database  
 Log Kow used by Water solubility estimates: 6.76

Equation Used to Make Water Sol estimate:  
 $\text{Log S (mol/L)} = 0.796 - 0.854 \log \text{Kow} - 0.00728 \text{ MW} + \text{Correction}$   
 (used when Melting Point NOT available)

Correction(s):      Value  
 -----  
 No Applicable Correction Factors

Log Water Solubility (in moles/L) : -6.724  
 Water Solubility at 25 deg C (mg/L): 0.045

**Source** : Arkema Inc. Philadelphia, PA USA  
**Reliability** : (2) valid with restrictions  
 22.12.2005

(4)

## 2.6.1 SOLUBILITY IN DIFFERENT MEDIA

**Solubility in** : Water  
**Value** : ca. .045 mg/l at 25 °C  
**pH value** :  
**concentration** : at °C  
**Temperature effects** :  
**Examine different pol.** :  
**pKa** : at 25 °C  
**Description** :  
**Stable** :  
**Deg. product** :  
**Method** : other: estimate  
**Year** :  
**GLP** :  
**Test substance** :

**Source** : Arkema Inc. Philadelphia, PA USA  
**Reliability** : (2) valid with restrictions  
 22.12.2005

(4)

**Solubility in** : Water  
**Value** : ca. .0006 mg/l at °C  
**pH value** :  
**concentration** : at °C  
**Temperature effects** :

## 2. Physico-Chemical Data

**Id** 7320-37-8

**Date** 23.12.2005

**Examine different pol.** :  
**pKa** : at 25 °C  
**Description** :  
**Stable** :  
**Deg. product** :  
**Method** : other  
**Year** :  
**GLP** :  
**Test substance** :

**Method** : Estimate based on structure  
23.12.2005

(26)

### 2.6.2 SURFACE TENSION

### 2.7 FLASH POINT

**Value** : 93 °C  
**Type** :  
**Method** : other: closed cup  
**Year** :  
**GLP** :  
**Test substance** :

**Source** : Arkema Inc. Philadelphia, PA USA  
**Reliability** : (2) valid with restrictions  
22.12.2005

(21)

### 2.8 AUTO FLAMMABILITY

### 2.9 FLAMMABILITY

### 2.10 EXPLOSIVE PROPERTIES

### 2.11 OXIDIZING PROPERTIES

### 2.12 DISSOCIATION CONSTANT

### 2.13 VISCOSITY

### 2.14 ADDITIONAL REMARKS



#### 3.1.1 PHOTODEGRADATION

#### 3.1.2 STABILITY IN WATER

#### 3.1.3 STABILITY IN SOIL

#### 3.2.1 MONITORING DATA

#### 3.2.2 FIELD STUDIES

#### 3.3.1 TRANSPORT BETWEEN ENVIRONMENTAL COMPARTMENTS

Type : fugacity model level III  
Media :  
Air : % (Fugacity Model Level I)  
Water : % (Fugacity Model Level I)  
Soil : % (Fugacity Model Level I)  
Biota : % (Fugacity Model Level II/III)  
Soil : 31.2 % (Fugacity Model Level II/III)  
Method : other: model  
Year :  
  
Result : Level III Fugacity Model:  

	Mass Amount (percent)	Half-Life (hr)	Emissions (kg/hr)
Air	0.531	13.7	1000
Water	4.42	360	1000
Soil	31.2	720	1000
Sediment	63.8	3.24e+003	0

Persistence Time: 1.11e+003 hr

Source : EPI SUMMARY (v3.12)  
Arkema Inc. Philadelphia, PA USA  
21.12.2005

(4)

#### 3.3.2 DISTRIBUTION

#### 3.4 MODE OF DEGRADATION IN ACTUAL USE

#### 3.5 BIODEGRADATION

Type : aerobic  
Inoculum :  
Contact time :  
Degradation : = 26 (±) % after 20 day(s)  
Result :

### 3. Environmental Fate and Pathways

**Id** 7320-37-8

**Date** 23.12.2005

**Deg. product** :  
**Method** :  
**Year** :  
**GLP** : yes  
**Test substance** :

**Remark** : Data provided by Dow.  
**Source** : Arkema Inc. Philadelphia, PA USA  
**Reliability** : (2) valid with restrictions  
22.12.2005

(24)

**Type** : aerobic  
**Inoculum** :  
**Deg. product** :  
**Method** : other: Modeled estimate  
**Year** :  
**GLP** :  
**Test substance** :

**Result** : Probability of Rapid Biodegradation (BIOWIN v4.01):  
Linear Model : 0.3942  
Non-Linear Model : 0.1201  
Expert Survey Biodegradation Results:  
Ultimate Survey Model: 2.9575 (weeks )  
Primary Survey Model : 3.7602 (days )  
Readily Biodegradable Probability (MITI Model):  
Linear Model : 0.6733  
Non-Linear Model : 0.766

**Source** : Arkema Inc. Philadelphia, PA USA  
22.12.2005

#### 3.6 BOD5, COD OR BOD5/COD RATIO

#### 3.7 BIOACCUMULATION

#### 3.8 ADDITIONAL REMARKS

## 4.1 ACUTE/PROLONGED TOXICITY TO FISH

Type	: semistatic
Species	: <i>Lebistes reticulatus</i> (Fish, fresh water)
Exposure period	: 14 day(s)
Unit	: µmol/l
Method	: Five concentrations geometrically increasing with a factor of 1,8 were tested for each material, exposing 10 fish to each concentration. Actual concentrations were measured at least four times after and four times before renewal. Concentrations were determined using G-LC with an FID detector.
Result	: For 1,2-epoxyhexadecane no LC50 could be determined. It is likely that the solubility of this compound is too low to cause lethal effects.
Conclusion	: LC50 value is greater than the limit of water solubility.
Reliability	: (2) valid with restrictions
23.12.2005	(2)
Type	: other: model estimate
Species	:
Exposure period	:
Unit	: mg/l
LC50	: ca. .323 calculated
Method	: other: ECOSAR V0.99
Year	:
GLP	:
Test substance	:
Result	: ECOSAR v0.99h Class(es) Found ----- Epoxides Predicted Values: Neutral Organic SAR: Fish, 14-day LC50 0.023 mg/l* (Baseline Toxicity)  Epoxides: Fish, 96-hr LC50 0.323 mg/l * Epoxides: Fish, 14-day LC50 0.351 mg/l *  Note: * = asterisk designates: Chemical may not be soluble enough to measure this predicted effect. Fish and daphnid acute toxicity log Kow cutoff: 5.0 MW cutoff: 1000
Source	: Arkema Inc. Philadelphia, PA USA
22.12.2005	(4)

## 4.2 ACUTE TOXICITY TO AQUATIC INVERTEBRATES

Type	: static
Species	: <i>Daphnia magna</i> (Crustacea)
Exposure period	:
Unit	: mg/l
EC50	: = 1.25 measured/nominal
Method	:
Year	:
GLP	: yes
Test substance	:

## 4. Ecotoxicity

Id 7320-37-8

Date 23.12.2005

**Source** : Arkema Inc. Philadelphia, PA USA  
**Reliability** : (2) valid with restrictions  
22.12.2005 (3) (24)

**Type** : other: modeled estimate  
**Species** : Daphnia sp. (Crustacea)  
**Exposure period** : 48 hour(s)  
**Unit** : mg/l  
**EC50** : ca. .038 calculated

**Result** : ECOSAR v0.99g Class(es) Found: Epoxides  
Predicted Daphnid 48-hr LC50 0.038 mg/L (ppm) \*  
Note: \* = asterisk designates: Chemical may not be soluble enough to measure this predicted effect.  
Fish and daphnid acute toxicity log Kow cutoff: 5.0  
MW cutoff: 1000

**Source** : Arkema Inc. Philadelphia, PA USA  
28.05.2004

### 4.3 TOXICITY TO AQUATIC PLANTS E.G. ALGAE

### 4.4 TOXICITY TO MICROORGANISMS E.G. BACTERIA

**Type** : aquatic  
**Species** :  
**Exposure period** :  
**Unit** : mg/l  
**EC10** : measured/nominal  
**EC50** : = 5000  
**Method** :  
**Year** :  
**GLP** : yes  
**Test substance** :

**Source** : Arkema Inc. Philadelphia, PA USA  
Data provided by Dow  
**Reliability** : (2) valid with restrictions  
22.12.2005 (3) (24)

#### 4.5.1 CHRONIC TOXICITY TO FISH

#### 4.5.2 CHRONIC TOXICITY TO AQUATIC INVERTEBRATES

#### 4.6.1 TOXICITY TO SEDIMENT DWELLING ORGANISMS

#### 4.6.2 TOXICITY TO TERRESTRIAL PLANTS

#### 4.6.3 TOXICITY TO SOIL DWELLING ORGANISMS

## 4. Ecotoxicity

**Id** 7320-37-8  
**Date** 23.12.2005

### 4.6.4 TOX. TO OTHER NON MAMM. TERR. SPECIES

### 4.7 BIOLOGICAL EFFECTS MONITORING

### 4.8 BIOTRANSFORMATION AND KINETICS

### 4.9 ADDITIONAL REMARKS

## 5.0 TOXICOKINETICS, METABOLISM AND DISTRIBUTION

<b>In Vitro/in vivo</b>	:	In vitro
<b>Type</b>	:	Metabolism
<b>Species</b>	:	other: mammalian liver
<b>Number of animals</b>		
<b>Males</b>	:	
<b>Females</b>	:	
<b>Doses</b>		
<b>Males</b>	:	
<b>Females</b>	:	
<b>Vehicle</b>	:	
<b>Method</b>	:	
<b>Year</b>	:	1975
<b>GLP</b>	:	no
<b>Test substance</b>	:	other TS
<b>Method</b>	:	<p>1-Hexadecene dissolved in acetone and suspended in 0.1 M phosphate buffer, pH 7.4, was incubated with rabbit liver microsomes in the presence of an NADPH-generating system. The reaction was terminated by the addition of sodium hydroxide, and the mixture extracted with ether containing 1,2-epoxytetradecane or 1,2-dihydroxytetradecane as the internal reference for the quantitative determination of metabolites. The ethereal extract was subjected to preparative silica gel thin-layer chromatography developed in benzene-acetone (5:1). Authentic 1,2-dihydroxytetradecane and 1,2-dihydroxyhexadecane or 1,2-epoxytetradecane and 1,2-epoxyhexadecane co-chromatographed as single bands at R<sub>f</sub> 0.2 or 0.7, respectively. Each zone of the chromatogram was eluted with ethanol. The eluate from the R<sub>f</sub> 0.2 zone was trimethylsilylated after the evaporation of the solvent and analyzed by gas-chromatography mass spectroscopy. Gas-chromatographic data (retention time: 7.4 min on a 2% OV-17 column at 210 C) and the mass spectrum were identical with those of authentic 1,2-dihydroxyhexadecane di-trimethylsilyl ether; a molecular ion peak with m/e 402 appeared together with fragment ion peaks characteristic of the glycol-TMS derivative at m/e 103 (strong intensity, TMS O CH<sub>2</sub> +) and 299 (strong intensity, TMS--O- CH<sub>2</sub>---(CH<sub>2</sub>)<sub>13</sub>CH<sub>3</sub>). The eluate from R<sub>f</sub> 0.7 zone was concentrated and directly analyzed by gas-chromatography-mass spectroscopy. Gas-chromatographic data (retention time: 4.5 min under the above conditions) and the mass spectrum obtained were identical with those of authentic 1,2-epoxyhexadecane; a molecular ion peak with m/e 240 appeared together with fragment ion peaks with m/e 57 (strong intensity) and 43.</p>
<b>Result</b>	:	<p>The formation of the epoxide was observed only when the olefin was incubated in the presence of the epoxide hydro-lase inhibitor 1,2-epoxydecane (10 mM). These results indicate that 1-hexadecene is metabolized to 1,2-dihydroxyhexadecane via 1,2-epoxyhexadecane.</p> <p>Enzymatic conversion of the epoxide to the glycol by rabbit liver microsomes has previously been reported.</p>
<b>Source</b>	:	ATOFINA Chemicals Inc. Philadelphia
<b>Test substance</b>	:	1-Hexadecene
<b>Conclusion</b>	:	This study corroborates the enzymatic conversion of the

## 5. Toxicity

Id 7320-37-8

Date 23.12.2005

epoxide to the glycol by rabbit liver microsomes as previously reported.  
**Reliability** : (1) valid without restriction (25)  
08.12.2005

### 5.1.1 ACUTE ORAL TOXICITY

**Type** : LD50  
**Value** : > 5000 mg/kg bw  
**Species** : rat  
**Strain** : Sprague-Dawley  
**Sex** : male/female  
**Number of animals** : 10  
**Vehicle** :  
**Doses** : 5000 mg/kg bw  
**Method** :  
**Year** :  
**GLP** : yes  
**Test substance** :

**Method** : The single-dose oral toxicity was evaluated in Sprague-Dawley rats. A limit test was performed in which one group of five male and five female rats received a single oral administration of the test article at a dose of 5000 mg/kg body weight. Following dosing, the limit test rats were observed daily and weighed weekly. A gross necropsy examination was performed on all limit test animals at the time of scheduled euthanasia (day 14).

**Result** : Year study performed: 1996  
No mortality occurred during the limit test. The most notable clinical abnormalities observed during the study included fecal/urine stain, rough haircoat, dark material around nose, scabs/reddened skin/hairloss and/or swelling on various areas, decreased defecation and soft stools. Body weight gain was noted for all animals during the test period. No significant gross internal findings were observed at necropsy on study day 14.

**Source** : Arkema Inc. Philadelphia, PA USA  
**Test condition** : Young adult rats were used.  
**Test substance** : Vikolox (R) 16  
**Conclusion** : Under the conditions of this test, the acute oral LD50 was estimated to be greater than 5000 mg/kg in the rat.  
**Reliability** : (1) valid without restriction  
**Flag** : Critical study for SIDS endpoint  
22.12.2005 (16)

### 5.1.2 ACUTE INHALATION TOXICITY

### 5.1.3 ACUTE DERMAL TOXICITY

**Type** : LD50  
**Value** : > 2000 mg/kg bw  
**Species** : rat  
**Strain** : Sprague-Dawley  
**Sex** : male/female  
**Number of animals** : 10

## 5. Toxicity

Id 7320-37-8

Date 23.12.2005

**Vehicle** :  
**Doses** : 2000 mg/kg  
**Method** :  
**Year** :  
**GLP** : yes  
**Test substance** :

**Method** : The single-dose dermal toxicity was evaluated on Sprague-Dawley rats. A limit test was performed in which one group of five male and five female rats received a single dermal administration of the test article. The test article was administered as received from the Sponsor. April 8, 1996 (GLP initiation date)

**Result** : No mortality occurred during the limit test. Clinical abnormalities observed during the study included urine stain and dark material around the facial area. Dermal irritation was noted at the site of test article application. Body weight loss was noted in four females during the day 0 to 7 body weight interval. One female did not regain her original body weight by study day 14. Body weight gain was noted for all other animals during the test period. No significant gross internal findings were observed at necropsy on study day 14.

**Source** : Arkema Inc. Philadelphia, PA USA  
**Test condition** : On day -1, the fur was removed from the dorsal trunk area (~ 10% of the animal's body surface area) of the animals chosen for the limit test using an animal clipper. Young adult, Sprague-Dawley Crl:CD®BR VAF/Plus® rats received a dose of 2000 mg/kg body weight. The density of the test article was determined to be 0.85 g/mL. On the following day (day 0), the test article was administered dermally to approximately 10% of the body surface area (BSA). The test article was spread evenly over the test area and held in contact with the skin with an appropriately sized 4 ply porous gauze dressing backed with a plastic wrap which was placed over the gauze dressing (occlusive binding). Removal and ingestion of the test article was prevented by placing an elastic wrap over the trunk and test area. The elastic wrap was further secured with a tape harness on the cranial end of the trunk and then secured with adhesive tape around the trunk at the caudal end.

After an approximate 24-hour exposure period, the gauze dressing, plastic and elastic wrap were removed and the corners of the test site delineated using a marker. Residual test article was removed using gauze moistened with distilled water followed by dry gauze.

Following dosing, the limit test rats were observed daily and weighed weekly. A gross necropsy examination was performed on all limit test animals at the time of scheduled euthanasia (day 14).

**Test substance** : Vikolox 16  
**Conclusion** : Under the conditions of this test, the acute dermal LD50 of Vikolox 16 was estimated to be greater than 2000 mg/kg in the rat.

**Reliability** : (1) valid without restriction  
22.12.2005

(19)

**Type** : LD50  
**Value** : = 10 ml/kg bw  
**Species** :



## 5. Toxicity

Id 7320-37-8

Date 23.12.2005

Strain :  
Sex :  
Number of animals :  
Vehicle :  
Doses :

Source : Arkema Inc. Philadelphia, PA USA  
Reliability : (2) valid with restrictions  
22.12.2005

(13)

### 5.1.4 ACUTE TOXICITY, OTHER ROUTES

Type : LD50  
Value : = 4.92 ml/kg bw  
Species : rat  
Strain :  
Sex :  
Number of animals :  
Vehicle :  
Doses :  
Route of admin. : i.p.  
Exposure time :  
Source : Arkema Inc. Philadelphia, PA USA  
Data provided by Dow Chemical Company  
Reliability : (2) valid with restrictions  
22.12.2005

(24)

### 5.2.1 SKIN IRRITATION

Species : rabbit  
Concentration : undiluted  
Exposure : Semiocclusive  
Exposure time : 4 hour(s)  
Number of animals : 6  
Vehicle :  
PDII : 5  
Result : highly irritating  
Classification : irritating  
Method :  
Year :  
GLP : yes  
Test substance :

Method : The potential irritant and/or corrosive effects were evaluated on the skin of New Zealand White rabbits. April 8, 1996 (GLP initiation date)

Result : Exposure to the test article produced slight edema and blanching greater than 50% of the test site on 6/6 test sites at the 1 hour scoring interval. The dermal irritation resolved completely in all animals by study day 14. An additional dermal finding included desquamation, which was noted in all animals during the study but which resolved between days 9 and 14 in all cases.

Average scores  
TIME ERY EDEMA  
1 Hour 4 2  
24 Hours 3.7 2

## 5. Toxicity

Id 7320-37-8

Date 23.12.2005

48 Hours 3.3 1.2  
72 Hours 3.3 1  
7 Days 1.2 0  
9 Days 0.8 0  
10 Days 1 0  
14 Days 0 0

**Source**

: Arkema Inc. Philadelphia, PA USA

**Test condition**

: Each of six adult, New Zealand White rabbits received a 0.5 mL dose of the test article as a single dermal application. The test article was administered as received from the Sponsor. The test article was placed in a beaker, heated and maintained in a water bath at 37°C. Test article was heated to liquefy but was not diluted to a concentration. On day -1, the fur was removed from the dorsal area of the trunk using an animal clipper. On the following day (day 0), the test article was applied to a small area of intact skin on each test animal (approximately 1 inch x 1 inch). The test article was administered under the gauze patch covered by an elastic wrap over the trunk and test area (semi-occlusive binding). The elastic wrap was then further secured with adhesive tape around the trunk at the cranial and caudal ends. After a four-hour exposure period, the elastic wrap and gauze patch were removed. Residual test article was removed using gauze moistened with distilled water followed by dry gauze. Test sites were subsequently examined and scored for dermal irritation for up to 14 days following patch removal.

**Test substance  
Conclusion**

: Animals were examined for signs of erythema and edema and the responses scored at approximately 1, 24, 48 and 72 hours and up to 14 days after patch removal according to the Macroscopic Dermal Grading System which is based on Draize.  
: Vikolox (R) 16  
: Under the conditions of this test, the material is considered to be an irritant to the skin of the rabbit.

**Reliability**  
22.12.2005

: (1) valid without restriction

(18)

**Species**  
**Concentration**  
**Exposure**  
**Exposure time**  
**Number of animals**  
**Vehicle**  
**PDII**  
**Result**  
**Classification**  
**Method**  
**Year**  
**GLP**  
**Test substance**

: rabbit  
:  
:  
:  
:  
:  
: 3.8  
: moderately irritating  
:  
:  
:  
:  
:

**Result**  
**Source**  
22.12.2005

: moderate (Draize score - 3.8)  
: Arkema Inc. Philadelphia, PA USA

(8)

**Species**  
**Concentration**  
**Exposure**  
**Exposure time**

:  
:  
:  
:

## 5. Toxicity

Id 7320-37-8

Date 23.12.2005

Number of animals :  
Vehicle :  
PDII :  
Result : moderately irritating  
Classification : irritating  
Method :  
Year :  
GLP :  
Test substance :

Source : Arkema Inc. Philadelphia, PA USA  
22.12.2005

(13)

### 5.2.2 EYE IRRITATION

Species : rabbit  
Concentration : undiluted  
Dose : .1 ml  
Exposure time :  
Comment :  
Number of animals : 6  
Vehicle :  
Result :  
Classification : irritating  
Method :  
Year :  
GLP : yes  
Test substance : as prescribed by 1.1 - 1.4

**Method** : The potential irritant and/or corrosive effects were evaluated on the eyes of New Zealand White rabbits. April 8, 1996 (GLP initiation date)

**Result** : ocular irritation score = [corneal opacity x area x 5] + [iritis x 5] + [(conjunctival redness + swelling + discharge) x 2]  
The group mean irritation score was then calculated for each scoring interval based on the number of animals initially dosed in each group.

Exposure to the test article produced iritis in 2/6 test eyes at the 1 hour scoring interval which resolved completely in the affected eyes by the 24 hour scoring interval. Conjunctivitis (redness, swelling and discharge) was noted in 6/6 test eyes at the 1 hour scoring interval. The conjunctival irritation resolved completely in all animals by study day 7. No corneal opacity, iritis or conjunctivitis was observed in the control eyes.

**Source** : Slightly irritating, Draize index 2 (110 = Maximum possible score)  
Arkema Inc. Philadelphia, PA USA  
**Test condition** : Each of six rabbits received a 0.1 mL dose of the test article in the conjunctival sac of the right eye. The test article was heated in a 37°C water bath and maintained at room temperature. The test article was heated to liquefy but was not diluted. The contralateral eye of each animal remained untreated and served as a control.

Prior to dosing, eyes of each animal were examined for ocular irritation with the aid of an auxiliary light source and the corneal surface was examined using fluorescein sodium dye. Animals exhibiting ocular irritation,

## 5. Toxicity

**Id** 7320-37-8

**Date** 23.12.2005

preexisting corneal injury or fluorescein dye retention were not used on study.

	Concentration	Amount	No. of Animals	
Group	Instilled		Males	Females
No Rinse	100%	0.1 mL	1	5

The eyes were macroscopically examined with the aid of an auxiliary light source for signs of irritation at 1, 24, 48 and 72 hours and up to 7 days after dosing according to the Ocular Grading System based on Draize. Following macroscopic observations at the 24 hour scoring interval, the fluorescein examination procedure was repeated on all test and control eyes and any residual test article was gently rinsed from the eye at this time (if possible) using physiological saline. If any fluorescein findings were noted at 24 hours, a fluorescein exam was conducted on the affected eyes at each subsequent interval until a negative response was obtained.

**Test substance**  
**Conclusion**

: Vikolox (R) 16  
: Under the conditions of this test, this substance is considered to be an irritant to the ocular tissue of the rabbit.

**Reliability**  
22.12.2005

: (1) valid without restriction

(20)

**Species**  
**Concentration**  
**Dose**  
**Exposure time**  
**Comment**  
**Number of animals**  
**Vehicle**  
**Result**  
**Classification**  
**Method**  
**Year**  
**GLP**  
**Test substance**

: rabbit  
:  
:  
:  
:  
:  
:  
: slightly irritating  
:  
: Draize Test  
:  
:  
:

**Result**

: minor transient conjunctival irritation (Draize score - 2.0 at 24 hours)

**Source**  
22.12.2005

: Arkema Inc. Philadelphia, PA USA

(8)

**Species**  
**Concentration**  
**Dose**  
**Exposure time**  
**Comment**  
**Number of animals**  
**Vehicle**  
**Result**  
**Classification**  
**Method**  
**Year**  
**GLP**  
**Test substance**

:  
:  
:  
:  
:  
:  
:  
: not irritating  
: not irritating  
:  
:  
:  
:

**Source**  
22.12.2005

: Arkema Inc. Philadelphia, PA USA

(13)

## 5.3 SENSITIZATION

<b>Type</b>	: Buehler Test
<b>Species</b>	: guinea pig
<b>Concentration</b>	: 1 <sup>st</sup> : Induction 50 % occlusive epicutaneous 2 <sup>nd</sup> : Induction 50 % occlusive epicutaneous 3 <sup>rd</sup> : Induction 50 % occlusive epicutaneous
<b>Number of animals</b>	: 20
<b>Vehicle</b>	: other: mineral oil
<b>Result</b>	: sensitizing
<b>Classification</b>	:
<b>Method</b>	:
<b>Year</b>	:
<b>GLP</b>	: yes
<b>Test substance</b>	: other TS
<b>Method</b>	: This study was performed to assess the dermal sensitization potential (delayed contact hypersensitivity) in Hartley-derived albino guinea pigs when administered by multiple topical applications. May 14, 1996 (GLP initiation date).
<b>Result</b>	: A. Topical Range-Finding Studies: A test article concentration of 50% w/v in mineral oil was the maximum concentration that produced irritation. A concentration of 5% w/v in mineral oil was the highest non-irritating concentration and was therefore considered appropriate for challenge. B. Sensitization Study: Following Induction I @ 50% w/v in mineral oil, dermal scores of 1 were noted in 8/20 test animals at the 24 hour scoring interval and dermal scores of 1 to 2 (three with very slight edema) were noted in 13/20 test animals at the 48 hour scoring interval. At Induction II, which was performed on the same test site and concentration as Induction I, dermal scores of 2 to 3 (all with very slight to moderate edema and some with blanching and/or eschar) were noted in all test animals at both the 24 and 48 hour scoring intervals. This increase in dermal scores from Induction I to II may be partially attributed to primary irritation since the animals were dosed on the same test site. Following Induction III at 50% w/v, dermal scores of 2 to 3 (all with very slight to slight edema, 12/20 with blanching and 1/20 with eschar) were again noted in all test animals at the 24 hour scoring interval. At the 48 hour scoring interval, dermal scores of 1 to 3 (17/20 with very slight to slight edema and 7/20 with blanching) were noted in all test animals. Since Induction III was dosed on a naive test site, the increase in dermal scores when compared with Induction I is probably an indication of sensitization. Following challenge with 5% w/v in mineral oil, dermal scores of 1 to 2 (two with very slight edema) were noted in 11/20 test animals at the 24 hour scoring interval. At the 48 hour scoring interval, dermal scores of 1 were noted in 3/20 test animals. Dermal reactions in the remaining test and all challenge control animals were limited to scores of 0 to 1. Group mean dermal scores were noted to be slightly higher in the test animals as compared with the challenge control animals. Following rechallenge with 5% w/v in mineral oil, dermal scores of 1 to 2 (two with very slight edema) were noted in 10/20 test animals at the 24 hour scoring interval. At the 48 hour scoring interval, dermal scores of 1 to 2 (one with very slight edema) were noted in 6/20 test animals. Dermal reactions in the remaining test and all challenge control

## 5. Toxicity

Id 7320-37-8

Date 23.12.2005

	<p>animals were limited to scores of 0 to +. Group mean dermal scores were noted to be slightly higher in the test animals as compared with the challenge control animals. Following rechallenge with 15% w/v in mineral oil, dermal scores of 1 to 2 (most with very slight edema) were noted in 20/20 test animals at the 24 hour scoring interval and in 19/20 test animals at the 48 hour scoring interval. Dermal reactions in the remaining test and all challenge control animals were limited to scores of 0 to +/- . Group mean dermal scores were noted to be higher in the test animals as compared with the challenge control animals. Following rechallenge with 100% mineral oil, dermal scores of 0 to +/- were noted in all test and challenge control animals. Group mean dermal scores were noted to be similar in the test animals as compared with the challenge control animals.</p>
<b>Source</b>	: Arkema Inc. Philadelphia, PA USA
<b>Test condition</b>	: The test article was heated in a 37°C water bath (until liquefied). Young adult, Hartley-derived albino guinea pigs were used. Prior to dose administration, guinea pigs were weighed and the hair removed from the right and left side of the animals with a small animal clipper. Induction was accomplished with a 50% solution applied to 10 male and 10 female guinea pigs on days 1, 7 and 13. On the day prior to challenge dose administration, the test and challenge control animals were weighed and the hair was removed from the right side of the animals. On the day following clipping (day 27), a 5% solution was administered for 6 hours. A rechallenge was conducted in order to substantiate and clarify the challenge results. On the day prior to rechallenge dose administration, all test and challenge control animals were weighed and the hair was then removed from the right side and left side of the animals. On the day following clipping (day 34), challenge doses of 5% and 15% were applied on separate sites for 6 hours.
<b>Test substance</b>	: Vikolox (R) 16
<b>Conclusion</b>	: Based on the results of this study, this material is considered to be a contact sensitizer in guinea pigs. The results of the hexylcinnamaldehyde historical control study demonstrated that the test design utilized would detect potential contact sensitizers.
<b>Reliability</b>	: (1) valid without restriction
22.12.2005	(17)

### 5.4 REPEATED DOSE TOXICITY

<b>Type</b>	:	
<b>Species</b>	:	rat
<b>Sex</b>	:	male/female
<b>Strain</b>	:	Fischer 344
<b>Route of admin.</b>	:	dermal
<b>Exposure period</b>	:	13 weeks
<b>Frequency of treatm.</b>	:	daily; 5/week
<b>Post exposure period</b>	:	
<b>Doses</b>	:	0, 62.5 mg/kg, 125, 250, 500, 1000; conc : 0, 3.75, 7.5, 15. 30, 60%
<b>Control group</b>	:	yes, concurrent vehicle
<b>LOAEL</b>	:	= 125 mg/kg bw
<b>Method</b>	:	Method/guideline followed 90 day study

## 5. Toxicity

Id 7320-37-8

Date 23.12.2005

Test type Dermal skin painting  
GLP (Y/N) study was audited by NTP

Year (study performed) 1979  
Species rat  
Strain F344  
Route of administration dermal  
Doses/concentration levels 0, 62.5, 125, 250, 500, 1000  
conc : 0, 3.75, 7.5, 15. 30, 60%

Sex M & F  
Exposure period 90 days  
Frequency of treatment 5 days/week  
Control group and treatment Vehicle control  
Post exposure observation period 5 days  
Statistical methods none  
Age at study initiation 7 weeks  
No. of animals per sex per dose 10; group housed 5/sex/cage  
Vehicle Acetone  
Dose volume adjusted on weight basis  
Dose concentration 4% - 60%  
Clinical Observations Body weights weekly; 2x daily checks for signs and mortality, detailed observations 1/wk

Necropsy Gross pathology; organs examined: skin, lymph nodes (mandibular, mesenteric) mammary gland, salivary gland, thigh muscles, sciatic nerve, bone marrow, thymus, larynx, trachea, lungs and bronchi, heart, thyroid, parathyroid, esophagus, stomach, duodenum, jejunum, ileum, colon, rectum, liver, pancreas, spleen, kidneys, adrenals, bladder, seminal vesicles, prostate, testes, ovaries, uterus, nasal cavity, brain, pituitary, eyes, external and middle ear, spinal cord.

**Remark** : The data presented here were extracted from the records maintained at the NTP archives.  
Pathology QUALITY ASSESSMENT  
REPORT OF THE SUBCHRONIC STUDY OF EPOXY HEXADECANE (C55538)  
IN Fischer 344 Rats and B6C3F1 Mice

### RATS

There were lesions observed in this study. These skin lesions (site of application) were manifested in a variety of changes. changes consisted of hyperkeratosis, parakeratosis, acanthosis, necrosis of cells, and necrosis with varying degrees of inflammation. In more severe cases, mostly high dose and mid dose animals, there was ulceration of the skin accompanied with acute and chronic inflammation. In one case, high dose male, there were pyogenic granulomas deep in the dermis and muscle.

Lung lesions seen in this study are suggestive of being Sendi virus induced.

The reviewing pathologist concluded that there were no discrepancies noted which should alter the doses recommended for the chronic study.

**Result** : Body weights: consistently slightly to moderately reduced @ 500 & 1000 for males; at termination ~20 and 35% lower than controls, and from the second week of dosing @ 250, 500, and 1000 slightly to moderately reduced for females; at termination 9, 27, 4, and 70% lower than controls

## 5. Toxicity

Id 7320-37-8

Date 23.12.2005

Clinical signs: 62.5 mg/kg: (2 of 10 males) dark brown spots on treated areas weeks 3 - 8; weeks 9 - 13 hyperemic treatment area

250 mg/kg: weeks 3 - 9: all males exfoliation of stratum corneum; weeks 10 - 13 - sores on backs

500 mg/kg: weeks 3 - 8 - all animals exfoliation of stratum corneum and alopecia; in addition during weeks 9 -13 erythema and rough coats in some animals; some females thin

1000 mg/kg: weeks 1 - 3 rough coats and slight erythema; weeks 4 - 13 in addition exfoliation of the stratum corneum, week 5 - 13 dark urine, emaciation primarily in females, alopecia, sores in treated area.

Microscopic findings are limited to the skin and site of application. Deep dermal abscesses, focal ulceration, inflammation were reported.

Murine virus Antibody Determinations: PVM titers ranged from 80 - 40 in 10/10 animals, KRV titers of 160 to 640 in 4/0 animals and Sendi titers of 80 - 320 in 10/10 animals.

Mortality: none prior to study termination

**Source**  
**Test substance**

- : Arkema Inc. Philadelphia, PA USA
- : 1,2-epoxyhexadecane, Viking chemical Lot # P-2-305; Clear viscous liquid no precipitate; checked for stability and purity every 4 months; Titration with tetrabutyl ammonium iodide and standard perchloric acid indicates a purity of 91.8%; stable in acetone for 7 days diluted up to 10%.

Chemical Specification from Viking Chemicals Technical Bulletin for material used in NTP bioassay and supporting studies:

Acid Value (mg KOH/g) 0.20 max  
Oxirane Oxygen (theory - 6.66%) 6.12% min  
Peroxide number meq O/ 1,000 g 10 max  
Described as colorless cloudy liquid

**Conclusion**

- : LOAEL = 125 mg/kg. The most suitable level for a chronic study would be 125 mg/kg.

**Reliability**

- : (2) valid with restrictions  
During 1983 the US National Toxicology Program (NTP) staff evaluated a variety of problems associated with studies performed at the contractor, Gulf South Research Institute. A comprehensive quality assurance audit was performed and the decision was made to maintain the existing records at the NTP archives and to release limited data, without interpretations or conclusions as a special abridged report on the GSRI studies.

The data from the 1,2-epoxyhexadecane study was placed in a category considered data not fully reliable. The explanation is: None of the flaws in any study in this category would, if taken individually, seriously impact on the study; however, when viewed in toto, and in relation to the other studies or corporately, the collective flaws lead one to question the interpretability or unequivocal validity of the results. In most cases the flaws involve omission rather than commission and therefore a greater degree of good faith is required in accepting the results than the usual or typical study conducted for the NTP.



## 5. Toxicity

Id 7320-37-8

Date 23.12.2005

<p>In summary, while we have some confidence that the qualitative results (target organ identification and pathology) would be reasonably similar if the study was conducted again using the same exposure regimens, there is less certainty than one would desire in this respect and the quantitative results (magnitude of response) should be considered still less certain.</p>	
<p><b>Flag</b> 22.12.2005</p>	<p>: Critical study for SIDS endpoint (12)</p>
<p><b>Type</b> <b>Species</b> <b>Sex</b> <b>Strain</b> <b>Route of admin.</b> <b>Exposure period</b> <b>Frequency of treatm.</b> <b>Post exposure period</b> <b>Doses</b> <b>Control group</b> <b>LOAEL</b> <b>Method</b> <b>Year</b> <b>GLP</b> <b>Test substance</b></p>	<p>: : rat : male/female : Fischer 344 : dermal : 14 days : daily : : O, 2.5%, 5%, 10%, 20%, 40% applied 0.6 ml : yes, concurrent vehicle : = 2.5 % : : : : no data : other TS</p>
<p><b>Method</b></p>	<p>: Control group and treatment      Vehicle acetone Post exposure observation period      5 days Statistical methods      None Age at study initiation      8 weeks No. of animals per sex per dose      5 Vehicle      Acetone Clinical Observations      Body weights weekly Necropsy      Gross pathology</p>
<p><b>Remark</b></p>	<p>: The data presented here were extracted from the records maintained at the NTP archives.</p>
<p><b>Result</b></p>	<p>: Clinical signs: Rough coats, tissue necrosis of treated areas, dark urine; dose related body weight depression at all levels Gross necropsy findings: desquamation, alopecia, focal irritation of the skin Mortality: 1 female @ 20% and 2 females at 40%</p>
<p><b>Source</b> <b>Test substance</b></p>	<p>: Arkema Inc. Philadelphia, PA USA : 1,2-epoxyhexadecane, Viking chemical Lot # P-2-305; Clear viscous liquid no precipitate; checked for stability and purity every 4 months; Titration with tetrabutyl ammonium iodide and standard perchloric acid indicates a purity of 91.8%; stable in acetone for 7 days diluted up to 10%.</p>
<p><b>Conclusion</b></p>	<p>: Body weight data indicate a dose related effect with all test groups gaining less weight than controls and the 40% group losing more than 10 grams of body weight. At the 5% level and above, both sexes gained 19 to 150% less than controls. At the 2.5% level the males gained -14% and the females -6% relative to controls. Pathological changes consisted mostly of deaquamation and depilation at 10% and above.</p>
<p><b>Reliability</b> 22.12.2005</p>	<p>: (4) not assignable (11)</p>
<p><b>Type</b> <b>Species</b> <b>Sex</b></p>	<p>: : mouse : male/female</p>

## 5. Toxicity

Id 7320-37-8

Date 23.12.2005

**Strain** : B6C3F1  
**Route of admin.** : dermal  
**Exposure period** : 13 weeks  
**Frequency of treatm.** : 5 days/week  
**Post exposure period** :  
**Doses** : 0, 62.5 , 125, 250, 500, 1000 mg/kg  
**Control group** : yes, concurrent vehicle  
**LOAEL** : = 125 mg/kg bw  
**Method** :  
**Year** :  
**GLP** :  
**Test substance** : other TS

**Method** : Test type Dermal skin painting  
GLP (Y/N) no  
Year (study performed) 1979  
Species Mouse  
Strain B6C3F1  
Route of administration Dermal; applied to shaved skin of back ~ 1 sq inch area  
Duration of test 13 weeks  
Doses/concentration levels 0, 62.5 mg/kg, 125, 250, 500, 1000; conc : 0, 0.94%, 1.875, 3.75, 7.5, 15%  
Sex M & F  
Exposure period 90 days  
Frequency of treatment 5 days/week  
Control group and treatment Vehicle control  
Post exposure observation period 5 days  
Statistical methods None  
Age at study initiation 7 weeks  
No. of animals per sex per dose 10; group housed 5/sex/cage  
Vehicle Acetone  
Clinical Observations Body weights weekly; 2x daily checks for signs and mortality, detailed observations 1/wk;  
Necropsy  
Gross pathology; organs examined: skin, lymph nodes (mandibular, mesenteric) mammary gland, salivary gland, thigh muscles, sciatic nerve, bone marrow, thymus, larynx, trachea, lungs and bronchi, heart, thyroid, parathyroid, esophagus, stomach, duodenum, jejunum, ileum, colon, rectum, liver, pancreas, spleen, gall bladder, kidneys, adrenals, bladder, seminal vesicles, prostate, testes, ovaries, uterus, nasal cavity, brain, pituitary, eyes, external and middle ear, spinal cord.

**Remark** : Pathology QUALITY ASSESSMENT  
REPORT OF THE SUBCHRONIC STUDY OF EPOXY HEXADECANE (C55538)  
IN Fischer 344 Rats and B6C3F1 Mice

MICE  
Dose related lesions were encountered in the skin (target organ). The reviewing pathologist concluded that there were no discrepancies noted which should alter the recommendations for the chronic study. The lung lesions seen in this study are suggestive of being Sendi virus induced.

**Result** : Body weights: reduced body weights in males at > 250; beginning in the fourth week the mean body weights of the 1000 and 250 were slightly to moderately and 500 very slightly to slightly less than the controls. Mean body weights @ 500 dipped markedly during week 6 but recovered to near control values in week 7; mean body weights recovered

to near controls for all doses by end of the study; mean body weights of females varied too widely for any meaningful relationship to treatment.

Clinical signs: cutaneous reactions: exfoliation of the corneum layer of the skin, alopecia, hyperemia, and or blanching at application site @ > 250 in males and @ 1000 in females

Clinical observations: males:Control - sores on back likely due to fighting

250 mg/kg: sores on back likely due to fighting; Weeks 3 - 6 treatment area looks pale; week 7 some with thin appearance, Week 8 -- 2 found dead

500 mg/kg: weeks 3 - 6 - all animals exfoliation of stratum corneum and blanching of the skin; week 7 -- 4 found dead, survivors appear thin; weeks 7 -13: conditions of survivors improves

1000 mg/kg: weeks 1 - 2 exfoliation of the stratum corneum and alopecia of treated area; week 3 -- one found dead; week 7 -- 6 found dead; week 11 3 animals with sores on dorsal area; week 12 -- one found dead.

Clinical observations, females:250 mg/kg: weeks 3 - dark patches or blanching on treated area (1 each) Week 7 -- 3 found dead; Weeks 8-9 rough coats, thin; Weeks 8 - 13: conditions improve

500 mg/kg: Week 7: 3 found dead, others thin; Week 8: 1 found dead; Weeks 9 - 13 condition improves

1000 mg/kg: Week 1 slight erythema of treated area; week 2: exfoliation of the stratum corneum of treated area; weeks 3 - 6: exfoliation of the stratum corneum and alopecia of treated area; Week 6 one found dead; Week 7 -- 3 found dead; Weeks 7 - 13: thin appearance and continued dermal effects.

Microscopic findings -- hyperkeratosis (minimal to moderate) in 14 mice, parakeratosis in 3 mice, and epithelial hyperplasia in 8 mice. Except for the tissue changes in the skin of treated mice there were no tissue changes attributable to the effects of the test material in any of the treated mice examined. Mortality: 2m/3f @ 250; 4m/4f @ 500; 8m/4f @ 1000 mg/kg; most deaths occurred during weeks 6 - 8

**Source**  
**Test substance**

- : Arkema Inc. Philadelphia, PA USA
- : 1,2-epoxyhexadecane, Viking chemical Lot # P-2-305; Clear viscous liquid no precipitate; checked for stability and purity every 4 months; Titration with tetrabutyl ammonium iodide and standard perchloric acid indicates a purity of 91.8%; stable in acetone for 7 days diluted up to 10%.

**Conclusion**  
**Reliability**

- : LOAEL - 125 mg/kg. Treatment related dermal lesions
  - : (2) valid with restrictions
- During 1983 the US National Toxicology Program (NTP) staff evaluated a variety of problems associated with studies performed at the contractor, Gulf South Research Institute. A comprehensive quality assurance audit was performed and the decision was made to maintain the existing records at the NTP archives and to release limited data, without interpretations or conclusions as a special abridged report on the GSRI studies.

The data from the 1,2-epoxyhexadecane study was placed in a

category considered data not fully reliable. The explanation is: None of the flaws in any study in this category would, if taken individually, seriously impact on the study; however, when viewed in toto, and in relation to the other studies or corporately, the collective flaws lead one to question the interpretability or unequivocal validity of the results. In most cases the flaws involve omission rather than commission and therefore a greater degree of good faith is required in accepting the results than the usual or typical study conducted for the NTP.

In summary, while we have some confidence that the qualitative results (target organ identification and pathology) would be reasonably similar if the study was conducted again using the same exposure regimens, there is less certainty than one would desire in this respect and the quantitative results (magnitude of response) should be considered still less certain.

22.12.2005

(11)

**Type** :  
**Species** : mouse  
**Sex** : male/female  
**Strain** : B6C3F1  
**Route of admin.** : dermal  
**Exposure period** : 14 days  
**Frequency of treatm.** : daily  
**Post exposure period** : 5 days  
**Doses** : 0, 2.5%, 5%, 10%, 20%, 40% applied 0.2 ml  
**Control group** : yes, concurrent vehicle  
**NOAEL** : = 5 %  
**LOAEL** : = 10 %  
**Method** :  
**Year** :  
**GLP** :  
**Test substance** : other TS

**Method** : Method/guideline Range finding study for 90 day study  
 Test type 14 day dermal  
 Year (study performed) 1979  
 Species mouse  
 Strain B6C3F1  
 Route of administration dermal  
 Frequency of treatment daily  
 Vehicle acetone  
 Post exposure observation period 5 days  
 Statistical methods none  
 Age at study initiation 8 weeks  
 No. of animals per sex per dose 5  
 Clinical Observations Body weights weekly  
 Necropsy Gross pathology

**Remark** : The data presented here were extracted from the records maintained at the NTP archives.

**Result** : Body weights (grams)

	Males		Females	
	Start	End	Start	End
Control	28.0	28.4	20.4	22.0
2.5%	28.0	28.6	20.4	21.8
5%	27.6	30.2	19.4	22.6
10%	28.4	27.2	20.0	22.0
20%	28.8	26.4	19.4	18.6
40%	27.6	23.0	20.8	18.2

## 5. Toxicity

Id 7320-37-8

Date 23.12.2005

Gross necropsy records showed alopecia and small skin ulcers with the alopecia varying from focal area at the application site to 90% of the body. This alopecia was assumed to be compound related since large patches of hair were observed falling out during the test and this was not seen in controls. Clinical signs included tissue necrosis loss of equilibrium and difficulty walking. Mortality: all high dose females and 1 high dose male died during the 5 day post dosing observation period. No other mortalities.

**Source** : Arkema Inc. Philadelphia, PA USA

**Test substance** : 1,2-epoxyhexadecane, Viking chemical Lot # P-2-305; Clear viscous liquid no precipitate; checked for stability and purity every 4 months; Titration with tetrabutyl ammonium iodide and standard perchloric acid indicates a purity of 91.8%; stable in acetone for 7 days diluted up to 10%.

**Conclusion** : Body weight data indicate a probable toxic effect at 10% and above in males and 20% and above in females.

**Reliability** : (4) not assignable

22.12.2005

(11)

### 5.5 GENETIC TOXICITY 'IN VITRO'

**Type** : Salmonella typhimurium reverse mutation assay

**System of testing** :

**Test concentration** :

**Cycotoxic concentr.** :

**Metabolic activation** :

**Result** : negative

**Method** :

**Year** :

**GLP** :

**Test substance** :

**Source** : Arkema Inc. Philadelphia, PA USA

**Reliability** : (2) valid with restrictions

**Flag** : Critical study for SIDS endpoint

22.12.2005

(1)

**Type** : Salmonella typhimurium reverse mutation assay

**System of testing** :

**Test concentration** :

**Cycotoxic concentr.** :

**Metabolic activation** :

**Result** : negative

**Method** :

**Year** :

**GLP** :

**Test substance** :

**Source** : Arkema Inc. Philadelphia, PA USA

**Flag** : Critical study for SIDS endpoint

22.12.2005

(22)

**Type** : Sister chromatid exchange assay

**System of testing** : CHO cells

**Test concentration** :

**Cycotoxic concentr.** :

**Metabolic activation** :

**Result** : negative

## 5. Toxicity

**Id** 7320-37-8

**Date** 23.12.2005

**Method** :  
**Year** :  
**GLP** :  
**Test substance** :

**Source** : Arkema Inc. Philadelphia, PA USA  
**Reliability** : (2) valid with restrictions  
**Flag** : Critical study for SIDS endpoint  
22.12.2005

(15)

**Type** : Sister chromatid exchange assay  
**System of testing** : Chinese Hamster Cells  
**Test concentration** :  
**Cycotoxic concentr.** :  
**Metabolic activation** :  
**Result** : negative  
**Method** :  
**Year** :  
**GLP** :  
**Test substance** :

**Source** : Arkema Inc. Philadelphia, PA USA  
22.12.2005

(23)

**Type** : Ames test  
**System of testing** : TA98, TA100, TA1535, TA1537, TA1538  
**Test concentration** :  
**Cycotoxic concentr.** :  
**Metabolic activation** :  
**Result** : negative  
**Method** :  
**Year** :  
**GLP** :  
**Test substance** :

**Source** : Arkema Inc. Philadelphia, PA USA  
22.12.2005

(5)

**Type** : Mouse lymphoma assay  
**System of testing** :  
**Test concentration** :  
**Cycotoxic concentr.** :  
**Metabolic activation** :  
**Result** : positive  
**Method** :  
**Year** :  
**GLP** :  
**Test substance** :

**Source** : Arkema Inc. Philadelphia, PA USA  
22.12.2005

(6)

**Type** : Salmonella typhimurium reverse mutation assay  
**System of testing** :  
**Test concentration** :  
**Cycotoxic concentr.** :  
**Metabolic activation** :  
**Result** : negative  
**Method** :  
**Year** :  
**GLP** :  
**Test substance** :

## 5. Toxicity

Id 7320-37-8

Date 23.12.2005

Source : Arkema Inc. Philadelphia, PA USA  
22.12.2005

(9)

### 5.6 GENETIC TOXICITY 'IN VIVO'

### 5.7 CARCINOGENICITY

Species : rat  
Sex : male/female  
Strain : Fischer 344  
Route of admin. : dermal  
Exposure period : 2 years  
Frequency of treatm. : 5 days/week for 103 weeks  
Post exposure period : 1 week  
Doses : 125, 62.5 mg/kg  
Result :  
Control group : yes, concurrent vehicle  
Method :  
Year :  
GLP :  
Test substance :

Method : Method/guideline followed chronic bioassay  
Test type Dermal skin painting  
GLP (Y/N) study was audited by NTP  
Year (study performed) 1980  
Species rat  
Strain F344  
Route of administration dermal  
Doses/concentration levels 0, 62.5, 125  
conc : 0, 3.75, 7.5 (adjusted  
based on body weight to allow for administration of 600  
microliters)  
Sex M & F  
Exposure period 103 weeks  
Frequency of treatment 5 days/week  
Control group and treatment Vehicle control  
Post exposure observation period 5 days  
Statistical methods Fischers exact test  
no. of animals per sex per dose 50; group housed  
5/sex/cage  
Vehicle Acetone  
Clinical Observations Body weights weekly for  
first thirteen weeks then monthly; 2x daily checks for signs  
and mortality, detailed observations 1/wk and palpated for  
masses  
Interim sacrifices None  
Special studies None  
  
Moribund animals need for unscheduled  
sacrifice and necropsy determined by veterinarian or  
toxicologist; tissues preserved  
  
Necropsy  
  
Gross pathology: gross lesions and tissue masses and  
regional lymph nodes

## 5. Toxicity

Id 7320-37-8

Date 23.12.2005

organs examined:  
 adrenals,  
 bladder,  
 blood smear  
 brain (3 sections),  
 colon,  
 duodenum,  
 ear, external and middle  
 esophagus,  
 eyes,  
 heart,  
 ilem,  
 jejunum,  
 kidneys,  
 larynx,  
 liver,  
 lungs and bronchi,  
 lymph nodes (mandibular, mesenteric)  
 mammary gland,  
 nasal cavity,  
 ovaries,  
 pancreas,  
 parathyroid,  
 pituitary,  
 prostate,  
 rectum,  
 salivary gland,  
 sciatic nerve,  
 seminal vesicles,  
 skin,  
 small intestine (one section)  
 spinal cord.  
 spleen,  
 sternbrae, femur or vertebrae including bone marrow,  
 stomach,  
 testes,  
 thigh muscle,  
 thymus,  
 thyroid,  
 trachea,  
 uterus,

**Remark** : The data presented here were extracted from the records maintained at the NTP archives.

**Result** : No compound related toxicological effects were observed during most of the chronic study. No striking toxicological effects were observed when observation data for each treatment group was compared to controls.

Some non significant differences were seen between the groups for non-tumour pathology. Changes noted in the skin were significant and are listed below by sex and dose group

	Males			Females		
	%			%		
	C	low	high	c	low	high
Inflammation						
focal	2			2		
chronic		2	6	8	4	
chronic & focal		2		4	4	
acute				2		



## 5. Toxicity

Id 7320-37-8

Date 23.12.2005

acute & focal				2		
acute & chronic					2	
Hyperplasia						
NOS	2	4	32		26	26
epithelial	2					
focal	2			2		
Hyperkeratosis		12	18		2	12
Sclerosis						
dermis	2					

It is apparent that the test material is a skin irritant and induces proliferative changes when applied topically.

No consistent compound related reduction in body weight occurred in any of the treatment groups. Periodic weight fluctuations were attributed to problems with the automatic watering system.

Results of Post Pathology Working Group (PWG)  
PATHOLOGY NARRATIVE OF 1,2-EPOXYHEXADECANE (C55538) IN B6C3FI MICE AND FISCHER 344 RATS August 11, 1983

### Neoplastic Lesions

There was reported an increased incidence of adenomas of the anterior pituitary gland in female rats. These neoplasms are well circumscribed usually solid masses of a single cell type that are moderately well demarcated from, and compress, surrounding tissue. Areas of trabecular formation are sometimes found and cavernous, blood-filled vessels often give the impression of hemorrhage in early lesions. In older, larger tumors the pools of blood may be lined with tumor cells rather than endothelium.

The PWG found additional tumors in all groups of female rats. In addition, there was unequal sampling among the groups with the greatest number of tissue specimens available in the test groups.

### Pituitary -Adenomas - Female Rats

	Control	Low Dose	High Dose
Original	13/50 (26%)	21/47 (45%)	18/48 (38%)

PWG	19/79 (24%)	25/104 (24%)	24/90 (26%)
-----	-------------	--------------	-------------

### Source Conclusion

- : Arkema Inc. Philadelphia, PA USA
- : RATS Pathology Working Group CONCLUSIONS  
1,2-Epoxyhexadecane in a two-year skin paint study did not produce any compound related neoplastic or systemic toxic lesions in F344 rats.

### Reliability

- : (2) valid with restrictions  
During 1983 the US National Toxicology Program (NTP) staff evaluated a variety of problems associated with studies performed at the contractor, Gulf South Research Institute. A comprehensive quality assurance audit was performed and the decision was made to maintain the existing records at the NTP archives and to release limited data, without interpretations or conclusions as a special abridged report on the GSRI studies.

The data from the 1,2-epoxyhexadecane study was placed in a category considered data not fully reliable. The explanation is: None of the flaws in any study in this

category would, if taken individually, seriously impact on the study; however, when viewed in toto, and in relation to the other studies or corporately, the collective flaws lead one to question the interpretability or unequivocal validity of the results. In most cases the flaws involve omission rather than commission and therefore a greater degree of good faith is required in accepting the results than the usual or typical study conducted for the NTP.

In summary, while we have some confidence that the qualitative results (target organ identification and pathology) would be reasonably similar if the study was conducted again using the same exposure regimens, there is less certainty than one would desire in this respect and the quantitative results (magnitude of response) should be considered still less certain.

22.12.2005

(11)

**Species** : mouse  
**Sex** : male/female  
**Strain** : B6C3F1  
**Route of admin.** : dermal  
**Exposure period** : 2 years  
**Frequency of treatm.** : 5 days/week for 103 weeks  
**Post exposure period** : 1 week  
**Doses** : 125, 62.5 mg/kg  
**Result** :  
**Control group** : yes, concurrent vehicle  
**Method** :  
**Year** : 1980  
**GLP** :  
**Test substance** :

**Method** : Test type Dermal skin painting  
 GLP (Y/N) Study audited by NTP  
 Year (study performed) 1980  
 Species Mouse  
 Strain B6C3F1  
 Route of administration Dermal; applied to shaved skin of back ~ 1 sq inch area  
 Duration of test 103 weeks  
 Dose levels 0, 62.5, 125 mg/kg concentrations adjusted based on body weight to allow administration of 200 microliters.  
 Sex M & F  
 Exposure period 103 weeks  
 Frequency of treatment 5 days/week  
 Control group and treatment Vehicle control  
 Post exposure observation period 5 days  
 Statistical methods None  
 No. of animals per sex per dose 50; group housed 5/sex/cage  
 Vehicle Acetone  
 Clinical Observations Body weights weekly for first 13 weeks then monthly; 2x daily checks for signs and mortality, detailed observations 1/wk and palpated for massed  
 Interim sacrifices None  
 Special studied None  
  
 Moribund animals need for unscheduled sacrifice and necropsy determined by veterinarian or toxicologist; tissues preserved

**Remark****Result**

## Necropsy

Gross pathology; organs examined: skin, lymph nodes (mandibular, mesenteric) mammary gland, salivary gland, thigh muscles, sciatic nerve, bone marrow, thymus, larynx, trachea, lungs and bronchi, heart, thyroid, parathyroid, esophagus, stomach, duodenum, jejunum, ileum, colon, rectum, liver, pancreas, spleen, gall bladder, kidneys, adrenals, bladder, seminal vesicles, prostate, testes, ovaries, uterus, nasal cavity, brain, pituitary, eyes, external and middle ear, spinal cord.

: The data presented here were extracted from the records maintained at the NTP archives.

: Pathology Working Group  
PATHOLOGY NARRATIVE OF 1,2-EPOXYHEXADECANE (C55538) IN B6C3FI MICE AND FISCHER 344 RATS August 11, 1983

1. All groups of male mice, including controls, had a high incidence of subcutaneous, mesenchymal neoplasms as follows:

Subcutaneous Neoplasms - Male Mice			
	Control	Low Dose	High Dose
Malignant			
Sarcoma NOS	1	3	4
Fibrosarcoma	2	4	5
Neurofibrosarcoma	1	-	-
Combined	4 (8%)	7 (14%)	9 (18%)
Benign			
Fibroma		1	4
Total Combined			
Incidence	5 (10X)	8 (16%)	13 (26%)

The distribution of the lesions on the body were back 19, abdomen 3, side 2 and leg and axilla one each. Only one fibrosarcoma was clearly identified as occurring at the application site. The tumors were all visible grossly and varied in size up to 6.0 x 3.5 x 2.4 cm.

Microscopically fibromas are composed of fusiform or stellate cells with pale, ovoid or rounded nuclei. The cells produce interlacing bundles of collagen fibers which may be densely packed or loosely arranged as if separated by edema or a mucinous ground substance. The tumors are relatively well circumscribed and non-invasive. Fibrosarcomas are more cellular and produce less collagen. They are locally invasive and may metastasize. Neurofibrosarcomas are similar to fibrosarcomas. They are characterized by bundles of cells and fibers that are arranged in whorls which when cut longitudinally produce a herring bone pattern. They are believed to arise from nerve sheaths. Many pathologists do not differentiate them from fibrosarcomas. Sarcoma NOS are extremely cellular tumors which may contain large bizarre nuclei, mitotic figures and multinucleated giant cells. A pattern of interwoven bundles of fusiform cells may be apparent but collagen fibers are difficult to demonstrate in any quantity even with polarized light. They may be locally invasive and metastasize.

2. There was a modest increase in the incidence of hepatocellular adenomas in all groups of male mice as follows:

## Hepatocellular Neoplasms - Male Mice

	Control	Low Dose	High Dose
Adenoma	13 (27%)	14 (29%)	11 (22%)
Carcinoma	4 (8%)	10 (21%)	9 (18%)
Combined			
Incidence	17 (34%)	24 (48%)	20 (40%)

The incidence of hepatocellular carcinoma was low in control male mice and average for treated animals.

Hepatocellular adenomas microscopically have well defined borders that may be scalloped and which compress the surrounding parenchyma. There are variations in cell morphology and absence of triads. Organization is of a solid or trabecular type or a combination of both. Solid areas are composed of closely packed cells resembling normal hepatocytes in which sinusoids are rarely seen. The trabecular type has a clear cut cord structure with sinusoids separating the cords. Cords may radiate from blood vessels giving a pseudo-lobular appearance. In some tumors fatty change or vacuolation of the cytoplasm is prominent.

Hepatocellular carcinomas also occur in solid, trabecular and mixed patterns. Cells comprising the solid pattern vary greatly in cell and nuclear size and giant cells with large hyperchromatic nuclei are frequently present. The trabecular pattern differs from that of the adenoma in that the cords are many cells thick. Dilation of the sinusoids produces disruption of the regular trabecular pattern and necrosis and hemorrhage is common.

**Source**  
**Test substance**

- : Arkema Inc. Philadelphia, PA USA
- : 1,2-epoxyhexadecane, Viking chemical Lot # P-2-305; Clear viscous liquid no precipitate; checked for stability and purity every 4 months; Titration with tetrabutyl ammonium iodide and standard perchloric acid indicates a purity of 91.8%; stable in acetone for 7 days diluted up to 10%.

**Conclusion**

- : The pathology working group concluded that 1,2-epoxyhexadecane in a two year skin painting study was associated with a dose-related increase in subcutaneous mesenchymal neoplasms in male B6C3F1 mice. A clear relationship between the location of the neoplasms and the area of skin exposure to the test compound cannot be established from the data except for one tumor.

**Reliability**

- : There were no other neoplastic or systemic toxic compound related effects in B6C3F1 mice. The pathology working group considered the modest increase in hepatocellular tumors in male mice not to be of biological significance.
- : (2) valid with restrictions
- : During 1983 the US National Toxicology Program (NTP) staff evaluated a variety of problems associated with studies performed at the contractor, Gulf South Research Institute. A comprehensive quality assurance audit was performed and the decision was made to maintain the existing records at the NTP archives and to release limited data, without interpretations or conclusions as a special abridged report on the GSRI studies.

The data from the 1,2-epoxyhexadecane study was placed in a category considered data not fully reliable. The

explanation is: None of the flaws in any study in this category would, if taken individually, seriously impact on the study; however, when viewed in toto, and in relation to the other studies or corporately, the collective flaws lead one to question the interpretability or unequivocal validity of the results. In most cases the flaws involve omission rather than commission and therefore a greater degree of good faith is required in accepting the results than the usual or typical study conducted for the NTP.

In summary, while we have some confidence that the qualitative results (target organ identification and pathology) would be reasonably similar if the study was conducted again using the same exposure regimens, there is less certainty than one would desire in this respect and the quantitative results (magnitude of response) should be considered still less certain.

22.12.2005

(11)

### 5.8.1 TOXICITY TO FERTILITY

### 5.8.2 DEVELOPMENTAL TOXICITY/TERATOGENICITY

### 5.8.3 TOXICITY TO REPRODUCTION, OTHER STUDIES

### 5.9 SPECIFIC INVESTIGATIONS

### 5.10 EXPOSURE EXPERIENCE

### 5.11 ADDITIONAL REMARKS

### 6.1 ANALYTICAL METHODS

### 6.2 DETECTION AND IDENTIFICATION

### 7.1 FUNCTION

### 7.2 EFFECTS ON ORGANISMS TO BE CONTROLLED

### 7.3 ORGANISMS TO BE PROTECTED

### 7.4 USER

### 7.5 RESISTANCE

**8.1 METHODS HANDLING AND STORING**

**8.2 FIRE GUIDANCE**

**8.3 EMERGENCY MEASURES**

**8.4 POSSIB. OF RENDERING SUBST. HARMLESS**

**8.5 WASTE MANAGEMENT**

**8.6 SIDE-EFFECTS DETECTION**

**8.7 SUBSTANCE REGISTERED AS DANGEROUS FOR GROUND WATER**

**8.8 REACTIVITY TOWARDS CONTAINER MATERIAL**



- (1) Canter DA, et al. Comparative Mutagenicity of Aliphatic Epoxides in Salmonella. *Mutat Res* 172(2):105-138, 1986. Negative.
- (2) Deneer JW, Sinnige TL, Seinen W and Hermens JLM, A Quantitative Structure Activity Relationship for the Acute Toxicity of Some Epoxy Compounds to the Guppy, *Aquatic Toxicology* 13: 195-204, 1988.
- (3) Dow Europe GMBH MSDS alpha-Olefin Epoxide C-16, 30/3/04
- (4) EPI Suite v3.12, modeling program, US EPA
- (5) Hengler, W.C., Slesinski, R.S. and Frank, F.R. (1984). a-olefin epoxide C-16 Salmonella/Microsome (Ames) bacterial mutagenicity assay.
- (6) McGregor DB, et al. Responses of the L5178Y TK+/TK- Mouse Lymphoma Cell Forward Mutation Assay: III. 72 Coded Chemicals. *Environ Mol Mutagen* 12(1):85-154, 1988.
- (7) MPBPWIN v1.41 modeling program in EPI Suite v 3.12, US EPA
- (8) Myers, R.C. and Christopher, S.M. (1992). .... cutaneous and ocular irritancy testing using the rabbit.
- (9) National Institute of Health. Comparative Mutagenicity of Aliphatic Epoxides in Salmonella. TSCA Section 4 submission. TSCATS Microfiche No. 522513
- (10) NIST/EPA Gas Phase Infrared Database. Internet Website: [webbook.nist.gov](http://webbook.nist.gov)
- (11) NTP Unpublished study (C55538)
- (12) NTP Unpublished study, Fiche C55538 GS SUBCHRONIC TEST 13
- (13) Nycum, J.S. (1968). Single dose toxicity and irritation studies on .... Epoxides
- (14) Safety and Toxicity Data prepared for 1,2-epoxyhexadecane by Tracor Jitco July 26, 1978.
- (15) Slesinski, R.S. and Frank, F.R. (1984). a-Olefin Epoxide C-16 in vitro Genotoxicity Studies: Sister Chromatid Exchange Test.
- (16) SPRINGBORN ENVIRONMENTAL SCIENCES Acute Oral Toxicity Study in Rats with Vikolox 16, SLI STUDY NO. 3255.80, 19 August 1996.
- (17) SPRINGBORN ENVIRONMENTAL SCIENCES Dermal Sensitization Study in Guinea Pigs with Vikolox 16, SLI STUDY NO. 3255.84, 10 Sept 1996.
- (18) SPRINGBORN ENVIRONMENTAL SCIENCES, Primary SKin Irritation Study in Rabbits with Vikolox 16, SLI STUDY NO. 3255.83 19 August 1996.
- (19) SPRINGBORN ENVIRONMENTAL SCIENCES. Acute dermal toxicity study in rats with Vikolox 16, SLI STUDY NO. 3255.81, 19 August 1996.

## 9. References

Id 7320-37-8

Date 23.12.2005

- (20) SPRINGBORN ENVIRONMENTAL SCIENCES. Primary Eye Irritation Study in Rabbits with Vikolox 16, SLI STUDY NO. 3255.82, 19 August 1996.
- (21) The Dictionary of Substances and Their Effects (DOSE, 3rd Electronic Edition)  
2005 by The Royal Society of Chemistry/Knovel Corp.
- (22) Union Carbide Corporation. Alpha-Olefin Epoxide C-16 Salmonella/Microsome (Ames) Bacterial Mutagenicity Assay With Cover Letter. TSCA 8(d) submission. TSCATS Microfiche No. 206602. 03/05/84.
- (23) von der Hude W, Carstensen S and Obe G. Structure-Activity Relationships of Epoxides: Induction of Sister- Chromatid Exchanges in Chinese Hamster V79 Cells. Mutat Res 249(1):55-70, 1991.
- (24) Waggy, G.T. (1992). Ecological fate and effects data on alpha-olefin epoxide C16.
- (25) Watabe, T and Yamada N. The biotransformation of 1-hexadecene to carcinogenic 1,2-epoxyhexadecane by hepatic microsomes. Biochemical Pharmacology 24: 1051-1053, 1975.
- (26) Wood WP, Properties Of Alkyl-Epoxides - Table I With Cover Letter, US Environmental Protection Agency EPA/OTS DOC 40-8277016, NTIS/OTS0508875, 1982

### 10.1 END POINT SUMMARY

### 10.2 HAZARD SUMMARY

### 10.3 RISK ASSESSMENT